The case for & against
Bull & Bear analysis
Bearish
Simulations Plus (NASDAQ: SLP) is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries, focusing on enhancing drug development processes and improving R&D efficiency. The company operates at the forefront of the health technology sector, particularly in pharmacokinetic and pharmacodynamic modeling. As demand for innovative drug development continues to rise, SLP is positioned to capitalize on the trend of increased investment in biopharmaceuticals.
Bull says
- ↑Q3 FY2026 revenue rose 7% YoY to $21.9M; net income $3.6M (EPS $0.18)
- ↑Adjusted EBITDA margin at 36% underscores strong operational efficiency
- ↑Altaris acquisition approved at $18.50/share, representing a 26% premium
- ↑Service revenue grew 20% YoY to $9.3M, boosting revenue diversification
- ↑High dividend yield (0.90%) and strong liquidity support shareholder returns
- ↑Positive analyst revisions reflect improved market sentiment on earnings
Bear says
- ↓Earnings yield negative, indicating weak return on capital
- ↓Leverage risk elevated with balance sheet vulnerabilities
- ↓Size concerns limit competitive scale against larger peers
- ↓Investigation into acquisition may delay closing and hurt confidence
- ↓Analyst consensus hold with $17.25 target suggests limited upside
- ↓High volatility risk could deter risk-averse investors
Earnings Call · Q2 2026 · Mgmt. Guidance
Updated 04-11-2026neutral
Transcript signals
Bull points
- total revenue increased 8% to $24.3 million this quarter, with software revenue increasing 9% and accounting for 60% of total revenue. Services revenue also increased by 8%, representing 40% of total revenue.
- discovery revenue, primarily from AdMet Predictor, increased 19% for the quarter, contributing 19% to total software revenue.
- we achieved average revenue per client of $148,000, and our renewal rate was 87%.
Bear points
- Clinical operations revenue, primarily from proficiency, declined 54% for the quarter and 58% for the trailing 12-month period, reflecting challenges in that segment.
- we've seen a decline in software renewal rates, with only 87% on a trailing 12-month basis, down from historical levels.
- Over the past quarter, AI-related competitive concerns have weighed on valuations across most software-based business models, and biosimulation has not been entirely immune to that sentiment.
Read full transcript analysis ›